DXCM Financial Facts
Product cost of sales: 47.5MTotal revenue: 148.6M
See Full Income Statement
Total liabilities and stockholders' equity: 361.9M
Commitments and contingencies (Note 4): 0
See Full Balance Sheet
DexCom, Inc. (DXCM) Earnings
|
Expand Research on DXCM
Next EPS Date | 4/25/24 | EPS Growth Rate | +58.8% |
---|---|---|---|
Average EPS % Beat Rate | +31.1% | Revenue Growth Rate | +22.7% |
Average % Move 1-Wk after EPS | -0.4% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
2/8/24 | Q423 | $0.50 | $0.43 | +$0.07 | $1.03B | $1.02B | = | Details | |||
10/26/23 | Q323 | $0.50 | $0.34 | +$0.16 | $975M | $939.19M | = | Details | |||
7/27/23 | Q223 | $0.34 | $0.23 | +$0.11 | $871.3M | $841.18M | = | Details | |||
2/9/23 | Q422 | $0.34 | $0.27 | +$0.07 | $815.2M | $809.35M | = | Details | |||
10/27/22 | Q322 | $0.28 | $0.24 | +$0.04 | $769.6M | $751.74M | = | Details | |||
4/27/23 | Q123 | $0.17 | $0.15 | +$0.02 | $741.5M | $720.67M | = | Details | |||
2/10/22 | Q421 | $0.68 | $0.85 | -$0.17 | $698.2M | $696.47M | = | Details | |||
7/28/22 | Q222 | $0.17 | $0.19 | -$0.02 | $696.2M | $700.45M | = | Details |